ArticleJournal of nanobiotechnology2025
Rational engineering of nanoplatforms with hierarchical targeting hepatic tumor and subcellular mitochondria for enhanced image-guided photodynamic therapy.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Photodynamic therapy: research progress and paradigm evolution from mechanism innovation to clinical breakthrough in cancers.Medical gas research · 2026Review
- Photodynamic therapy: A paradigm shift in overcoming drug‑resistant tuberculosis (Review).Molecular medicine reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The main challenge of photosensitizer in image-guided photodynamic therapy (PDT) is the balance between the high singlet oxygen yields and strong fluorescence performance, while simultaneously targeting certain types of cancer to achieve optimal effect in both imaging and therapy. Herein, a novel donor-acceptor system, engineered with silica coated quantum dots as the donor and a typical porphyrin (T790) as the acceptor, has been further integrated with hierarchical targeting strategy, which demonstrated capability of targeting both hepatic tumors and mitochondria. The prepared nanoparticles were found to exhibit high singlet oxygen generation of 0.86, bright red fluorescence, and a large Stokes shift of 285 nm. In vitro assays revealed that they accumulated within the mitochondria of malignant hepatocytes to induce apoptosis due to their high singlet oxygen generation and disrupt the mitochondrial membrane potential, thereby leveling proteins associated with apoptosis. In vivo studies with xenograft tumor model confirmed their excelllent fluorescence imaging capability and remarkable anti-tumor effects. Transcriptomic analysis further revealed the potential molecular mechanisms of donor-acceptor system in the PDT process. This work provides insights for elucidating the transcriptional regulation of image-guided photodynamic therapy and paves the way for the development of more efficient and precise treatment methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.